Skip to content
Screener

Price / book at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
4.6×+3.7×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.1×+0.7×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
3.2×-0.2×
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
14.9×+2.6×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
3.9×-0.4×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
22×+7.8×

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$2.23B+417%
Enterprise value$2.03B

Profitability

See full
Operating margin-183.2%
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

Based on the most recent quarter.

The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210463

FAQ

What is Palvella Therapeutics's price / book?
Palvella Therapeutics (PVLA) reported price / book of 7.7× in Q1 2026.
How has Palvella Therapeutics's price / book changed year-over-year?
Palvella Therapeutics's price / book increased by 35.9% year-over-year, from 5.7× to 7.7×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Palvella Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude